Amadeus invests in genetic testing pioneers, Igenomix

 Amadeus Capital Partners, the global technology investor, today announces that it has made a growth capital investment in Igenomix, the world’s leading in-vitro fertilization (IVF) genetic testing company, based in Valencia, Spain.

Igenomix’s main customers are the most reputable providers of fertility treatments across the world. Its genetic services encompass all phases of fertility treatment, through preconception, pre-implantation and pre-natal, providing tests that help parents to increase their chances of having a healthy baby by screening embryos for chromosome and single gene disorders.

Igenomix tested over 30,000 embryos in 2015 in its six laboratories in Valencia, Miami, Los Angeles, New Delhi, São Paulo and Dubai and has a team of over 140 employees of which 21% have PhDs. Amadeus Capital’s investment in the company will back its international expansion, with a special emphasis on the US market. Amadeus’s investment will also support the development of ground-breaking testing services at its leading laboratory in Valencia.

David Jimenez, Chief Executive Officer, Igenomix, commented on Amadeus Capital’s investment: “According to the World Health Organisation, infertility will be the third most serious disease this century. Approximately 1 out of 10 couples of reproductive age are currently infertile. Genetic testing will prove crucial in ensuring that treatments supporting fertility will be successful for families. Amadeus’ support as an investor, with a deep understanding of genetic technologies, will help Igenomix to progress our international development and fund research into new testing services.”

Andrea Traversone, Partner, Amadeus Capital Partners, added: “Amadeus Capital sees Igenomix as a compelling investment opportunity in a fast-growing sector of the healthcare market, based on major advances in genetic technology and improved access to IVF services. Igenomix has an exceptional management team in David Jimenez and Chief Scientific Officer Carlos Simon MD, PhD, recognised as a pioneer in IVF-related genetics, and we look forward to helping them build the business globally.”

In making this investment, Amadeus Capital Partners has joined a syndicate of investors including lead investor Charme Capital Partners, Aleph Capital and Graham Snudden.

Amadeus invests in Inotec’s advanced woundcare technology - NATROX™

Amadeus Capital Partners, the global technology investor, has today announced an investment in Inotec AMD, a maker of mobile medical devices designed to heal chronic, hypoxic wounds that afflict millions of sufferers around the world every year. As more than 90% of wounds suffer from a lack of oxygen, the launch of NATROX™ addresses this serious concern with a simple, cost-effective application which treats a broad spectrum of chronic health problems.

Amadeus Capital Partners will bring investment and expertise to Inotec, based in Cambridge, UK, to enable the company to carry out large scale clinical trials outside the UK and to broaden the scope of application of its innovative NATROX™ family of products. The global investor in dynamic start-ups will also draw on its worldwide network to help Inotec establish commercial agreements and grow its presence internationally.

Inotec was established in 2005 by Professor Derek Fray from Cambridge University and Mel Vinton. It’s compact and wearable NATROX™ system, which is CE marked and FDA approved, provides a continuous supply of pure humidified oxygen to wounds. In preliminary trials, NATROX™ has been shown to reduce the size of chronic wounds substantially within weeks, with a large number of patients’ wounds reaching complete healing.

“Inotec’s proprietary technology has the potential to profoundly improve standards of care for hard-to-heal and chronic wounds, a large and growing market, which has not been disrupted since negative therapy (VAC) was launched in the ‘90s. Being small and portable, NATROX™ can be used at home as well as in hospital, alleviating pressure on stretched healthcare systems and materially improving quality of life for patients,” said Pierre Socha, Investment Manager, Amadeus Capital Partners.

Trevor Stanley, Inotec CEO, commented, “The global wound-care market is projected to grow to $18.3 billion globally in 2019, driven in part by changing life styles and ageing populations in many countries. There are some 400 million diabetes sufferers around the world, some 60 million of whom are likely to develop a lower limb ulcer. Amadeus’ investment will enable us to deliver advanced and highly effective oxygen-based wound-care technology across the world.”